Peregrine Pharmaceuticals has achieved positive results demonstrating that its first-in-class anti-viral compound Tarvacin Anti-Viral appeared safe and well-tolerated in a Phase I study in chronic hepatitis C virus (HCV) infected patients. The data will support initiation of repeat dose and combination therapy trials that the company expects to begin later this year. In the ascending, single-dose trial, 24 patients with chronic HCV who had either failed or who no longer responded to standa...